Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center For Human Genetics And Laboratory Diagnostics, |
RCV001089531 | SCV001244885 | uncertain significance | Long QT syndrome 13 | 2019-09-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001305759 | SCV001495106 | uncertain significance | Long QT syndrome | 2024-12-17 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 384 of the KCNJ5 protein (p.Pro384Arg). This variant is present in population databases (rs148307402, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with KCNJ5-related conditions. ClinVar contains an entry for this variant (Variation ID: 869438). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt KCNJ5 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002355107 | SCV002624139 | uncertain significance | Cardiovascular phenotype | 2021-10-22 | criteria provided, single submitter | clinical testing | The p.P384R variant (also known as c.1151C>G), located in coding exon 2 of the KCNJ5 gene, results from a C to G substitution at nucleotide position 1151. The proline at codon 384 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005047299 | SCV005676502 | uncertain significance | Long QT syndrome 13; Familial hyperaldosteronism type III | 2024-01-02 | criteria provided, single submitter | clinical testing |